ELIGARD® Preparation, Mixing, and Injection Video

Skip to main content

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at https://aems.tga.gov.au/

Adverse events can also be reported to Mundipharma at Drugsafety@mundipharma.com.au

To help us respond to your query more efficiently, please include the following details in your email:

Your contact information
Patient identifier (e.g. initials, date of birth, or age – do not include full name)
Product details (name, batch number, etc.)
Description of the suspected adverse event

Report adverse event Login Register

country

country

AU

Australia (AU)
Brazil (BR)
France (FR)
Germany (DE)
Italy (IT)
Japan (JP)
Spain (ES)
United Kingdom (UK)

Therapy Areas
Medicines
Resources
About Us

Report adverse event

country

country

AU

Australia (AU)
Brazil (BR)
France (FR)
Germany (DE)
Italy (IT)
Japan (JP)
Spain (ES)
United Kingdom (UK)

Name

Surname

Your Email?

Reason for contact

Type your message here

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

* Required Fields

Leave this field blank

Report Adverse Event

Adverse events should be reported. Reporting forms and information can be found at https://aems.tga.gov.au/

Adverse events can also be reported to Mundipharma at Drugsafety@mundipharma.com.au

Home
Resources
Webinar & Video
ELIGARD® Preparation, Mixing, and Injection Video

ELIGARD^® Preparation, Mixing, and Injection Video

Related Video

Professor Declan Murphy

GU Cast Webinar - Case Study 2 - Biochemical Recurrence

Professor Declan Murphy

GU Cast Webinar - Case Study 1 - de novo mHSPC

Explaining the benefit of intensification therapy

Explaining the benefit of intensification therapy

Vote

You are one step away from accessing the content.

Please login or register to proceed.

country

country

AU

Australia (AU)
Brazil (BR)
France (FR)
Germany (DE)
Italy (IT)
Japan (JP)
Spain (ES)
United Kingdom (UK)

Therapy Areas
Medicines
Resources
About Us

CONTACT US
LEGAL
COOKIE POLICY
PRIVACY

Therapy Areas
Medicines
Resources
About Us

Copyright Mundipharma Pharmaceuticals. All Rights Reserved. | JOB CODE: AU-CRM-2500010 | Prepared: May 2025

STAY CONNECTED

Opioid Charter

Opioid Charter For Mundipharma's Charter on the responsible medical use of opioid analgesics in pain management Click Here..

Opioid Safety Statement

"Attention should be given as the use of opioids has a risk of addiction, misuse and abuse. Therefore, appropriate assessment and monitoring is required at initiation, maintenance and tapering down of opioid therapy."